Page 2 - Basket Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Basket study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Basket Study Today - Breaking & Trending Today

Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript

Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Genmab A/S (NASDAQ: GMAB)
Q4 2020 Earnings Call
[Operator Instructions]
During this telephone conference you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under an obligation to update statements regarding the future, nor to confirm such statements in relation to actual results unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy. ....

Tah Ahmadi , Carsten Lonborg Madsen , Peter Verdult Citi , Michael Novod Nordea , Anthony Pagano , Judith Klimovsky , Anthony Mancini , Wimal Kapadia , Trung Huynh , Janssen Duobody , Matthew Harrison Morgan Stanley , Michael Schmidt Guggenheim , Michael Novod , Peter Verdult , Matthew Harrison , Jonathan Chang , Wimal Kapadia Bernstein , Michael Schmidt , Morgan Stanley , Credit Suisse , Novo Nordisk , Motley Fool Genmab , Call Transcript , Motley Fool Logo , Investor Relations , Foolish Best ,

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021
Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021
The Company s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned ....

United States , United Kingdom , France General , Ricky Bhajun , Brandon Owens , Porter Novelli , Pierre Louis Germain , Nanobiotix Immuno , International Organization For Medical Physics , National Cancer Institute , Communications Department , French Financial Markets Authority Autorit , Company Nasdaq , American Society Of Clinical Oncology Gastrointestinal Symposium , Exchange Commission On , Investor Relations Department , American Society For Radiation Oncology , Oncology Program , European Union , Pharmaengine Inc , American Cancer Society , Drug Administration , World Health Organization , Expansion Study , Registrational Study , Soft Tissue ,